We describe the physiological function of heterologously expressed Mycobacterium tuberculosis InhA during de novo lipoic acid synthesis in yeast (Saccharomyces cerevisiae) mitochondria. InhA, representing 2-trans-enoyl-acyl carrier protein reductase and the target for the front-line antituberculous drug isoniazid, is involved in the activity of dissociative type 2 fatty acid synthase (FASII) that extends associative type 1 fatty acid synthase (FASI)-derived C 20 fatty acids to form C 60 -to-C 90 mycolic acids. Mycolic acids are major constituents of the protective layer around the pathogen that contribute to virulence and resistance to certain antimicrobials. Unlike FASI, FASII is thought to be incapable of de novo biosynthesis of fatty acids. Here, the genes for InhA (Rv1484) and four similar proteins (Rv0927c, Rv3485c, Rv3530c, and Rv3559c) were expressed in S. cerevisiae etr1⌬ cells lacking mitochondrial 2-trans-enoyl-thioester reductase activity. The phenotype of the yeast mutants includes the inability to produce sufficient levels of lipoic acid, form mitochondrial cytochromes, respire, or grow on nonfermentable carbon sources. Yeast etr1⌬ cells expressing mitochondrial InhA were able to respire, grow on glycerol, and produce lipoic acid. Commensurate with a role in mitochondrial de novo fatty acid biosynthesis, InhA could accept in vivo much shorter acyl-thioesters (C 4 to C 8 ) than was previously thought (>C 12 ). Moreover, InhA functioned in the absence of AcpM or protein-protein interactions with its native FASII partners KasA, KasB, FabD, and FabH. None of the four proteins similar to InhA complemented the yeast mutant phenotype. We discuss the implications of our findings with reference to lipoic acid synthesis in M. tuberculosis and the potential use of yeast FASII mutants for investigating the physiological function of drug-targeted pathogen enzymes involved in fatty acid biosynthesis.
Mycobacterium tuberculosis is the leading cause of mortality due to an infectious agent worldwide. The World Health Organization estimates that approximately 2 billion people have tuberculosis (53) . M. tuberculosis is therefore the biggest killer among human pathogens; it is thought that about 1.7 million people die from tuberculosis every year (www.who.int/tb /publications). Moreover, increasing multiple-drug resistance has contributed significantly to the number of incurable cases, and in some countries up to 36% of patients with tuberculosis are infected with strains resistant to isoniazid (INH) or rifampin (42) . These two compounds have been used clinically for several decades and are two of only a few first-line antituberculous drugs. The primary target of INH is InhA (3) , and this fact alone elevates InhA to the position of one of most medically significant pathogen proteins. Hence, it is important to use new molecular approaches to study InhA in order to identify novel ways of targeting this enzyme, as well as the processes in which it is involved.
InhA participates in fatty acid biosynthesis (3) . Unlike the situation in Escherichia coli, the mycobacterial process is comprised of two systems. M. tuberculosis has a prokaryotic dissociative type 2 fatty acid synthase (FASII) system, in which individual reactions are catalyzed by discrete polypeptides, a process that has been characterized extensively in E. coli and plant plastids. Additionally, M. tuberculosis has an associative type 1 fatty acid synthase (FASI) system (5), which includes several enzymatic activities within a multifunctional homohexamer and resembles the cytosolic synthase in eukaryotes (47) . The two systems combine to produce mycolic acids, which are very-long-chain (C 54 to C 63 ) ␣-branched, ␤-hydroxylated fatty acids that act with other factors to form the protective layer around the pathogen, thereby adding to its persistence despite lengthy treatment, and are also associated with its virulence (48) .
Based on its fully sequenced genome (13) , it has been proposed that M. tuberculosis contains the entire complement of FASII components (48) . The 2-trans-enoyl-acyl carrier protein (2-trans-enoyl-ACP) reductase of FASII is represented by InhA, which carries out the final step of the fatty acid elongation process. The M. tuberculosis genome harbors genes for four additional proteins, Rv0927c, Rv3485c, Rv3530c, and Rv3559c, that are all similar to InhA (48) and exhibit about 24 to 26% sequence identity to the latter protein (Fig. 1) . It has been proposed that in M. tuberculosis, InhA catalyzes the reduction of 2-trans-enoyl-ACPs with a chain length greater than C 12 , whereas InhA in Mycobacterium smegmatis acts on C 16 thioesters (35) .
Yeast (Saccharomyces cerevisiae), mammals, and other higher eukaryotes have traditionally been considered organ-isms that are capable of synthesizing fatty acids only through FASI. This view has very recently been completely overhauled, since an additional mitochondrial FASII has been discovered in both yeast and mammals (2, 28, 32, 37, 50, 55, 56) . In the first committed step of S. cerevisiae FASII activity, Hfa1p, representing mitochondrial acetyl coenzyme A (acetyl-CoA) carboxylase (29) , converts acetyl-CoA to malonyl-CoA. A malonylCoA transferase, mitochondrial Mct1p (45) , transfers the C 3 moiety to ACP, a mitochondrial protein encoded by ACP1 (46) . Chain elongation begins with the condensation of acetyl-ACP and malonyl-ACP by Cem1p (23), which acts as a mitochondrial 3-oxoacyl-ACP synthase. Mitochondrial Oar1p (45), a 3-oxoacyl-ACP reductase, produces the 3-hydroxyacyl-ACP intermediate, which is then dehydrated by mitochondrial Htd2p (32), a 3-hydroxyacyl-thioester dehydratase, to generate the 2-trans-enoyl-ACP species. The last step in each round of elongation is catalyzed by mitochondrial Etr1p representing 2-trans-enoyl-thioester reductase (50) .
A yeast mutant that lacks Etr1p contains abnormally small mitochondria, does not assemble respiratory complexes, and is exclusively fermentative (50, 54) . This phenotype can be rescued by supplying the mutant with the gene for fungal or human mitochondrial 2-trans-enoyl-ACP reductase (37, 50) . In addition, the etr1⌬ mutant phenotype can also be rescued with a mitochondrially targeted E. coli FabI protein (50), representing a structurally unrelated FASII enoyl-ACP reductase (4) . Whereas it has been proposed that mitochondrial FASII is involved in de novo production of the C 8 precursor of lipoic acid (20) , mycobacterial FASII is thought to be incapable of de novo synthesis (5) .
Here, we used S. cerevisiae as a surrogate for hosting M. tuberculosis protein genes (17) . To examine whether InhA could physiologically metabolize short-chain enoyl-ACP substrates and to determine whether there are functional InhA homologues in M. tuberculosis, InhA and the four similar proteins were expressed in the yeast etr1⌬ mutant, and transformed mutant cells were compared to cells of an otherwise isogenic strain expressing the corresponding native enzyme in terms of growth on glycerol, lipoic acid production, assembly of cytochrome complexes, respiration, and the presence of 2-trans-enoyl-thioester reductase activity. The implications of our finding that InhA can participate in de novo lipoic acid synthesis in yeast mitochondria for fatty acid biosynthesis in M. tuberculosis are briefly discussed below.
MATERIALS AND METHODS
Yeast strains, plasmids, and oligonucleotides. Yeast strains, plasmids, and oligonucleotides used are listed in Table 1 . E. coli strain DH10B was used for all plasmid amplification and isolation procedures. Transformation of yeast strains was performed using a previously described method (10) .
Plasmid construction. DNA manipulation and plasmid construction were performed using standard techniques (1) . Plasmid pPLM48, representing a YEp352-based multicopy plasmid (27) carrying the nucleotide sequence for a COQ3-inhA fusion encoding a mitochondrially targeted InhA (mit-InhA) driven by the oleic acid-inducible CTA1 promoter, was constructed as follows. PCR was performed with M. tuberculosis H37Rv genomic DNA using Phusion high-fidelity DNA polymerase (Finnzymes Oy, Espoo, Finland) and oligonucleotides Rv1484 MLSInhA F and Rv1484 InhA R (Table 1) , which introduced a 5Ј NcoI site and a 3Ј HindIII site, respectively, at an annealing temperature of 55°C. In amplification products preceded by an engineered NcoI site, the first nucleotide following the incorporated ATG triplet corresponding to the native translational start codon was replaced with G, when necessary, to accommodate the NcoI palindrome CCATGG. Electrophoretic resolution of the PCR mixture on a 0.7% (wt/vol) agarose gel in a buffer comprised of 40 mM Tris-acetate and 1 mM EDTA (pH 8.0) revealed a single amplification product of the correct size (approximately 900 bp), which was excised and purified using QIAquick spin columns according to the manufacturer's instructions (Qiagen, Valencia, CA). Following digestion with NcoI and HindIII restriction enzymes, the amplified inhA DNA was ligated behind the CTA1 promoter to a similarly digested pYE352:mitQOR plasmid (pPLM62) (see below), from which the QOR open reading frame (ORF) encoding E. coli quinone reductase was removed, leaving behind the nucleotides for the Coq3p (30) mitochondrial leader sequence (MLS). Nucleotide sequencing of the inhA insert verified that no mutations were introduced during the amplification process and that the COQ3-inhA junction remained intact.
To generate plasmid pPLM62, the E. coli mitQOR ORF was amplified from genomic DNA using oligonucleotides Ec qor ORF 5Ј NcoI and Ec qor ORF 3Ј XhoI and an annealing temperature of 55°C. The amplification product was digested with NcoI and XhoI and ligated to an XbaI-and XhoI-digested pYE352:CTA1 plasmid (16) , which was stored as pPLM51 in our strain collection, together with an NheI-and NcoI-delineated nucleotide sequence for the yeast Coq3p MLS, in a triple ligation reaction like that described previously for plasmid pYE352:mitfabI (50 (2) Expresses mitochondrial Coq3p-InhA (mit-InhA) from pPLM48 This study yPLM29 (2) Expresses mitochondrial Coq3p-Rv3485c from pPLM52 This study yPLM61 (2) Expresses mitochondrial Coq3p-Rv0927c from pPLM53 This study yPLM30 (2) Expresses mitochondrial Coq3p-Rv3530c from pPLM54 This study yPLM31 (2) Expresses mitochondrial Coq3p-Rv3559c from pPLM55 This study yPLM26 (2) Expresses mitochondrial Etr1p from pPLM50 50 yPLM25 (2) Expresses per-Cta1p from pPLM51 50 BJ1991
MAT␣ leu2 ura3-52 trp1 pep4-3 prb1-122 gal2 31 BJ1991etr1⌬ (3) ybr026c::KanMX4 50 YPLM242 (4) Expresses low levels of mit-InhA This study yPLM243 (4) Expresses low levels of mit-Etr1p This study yPLM244 (4) Harbors only the YCplac22 vector This study Plasmids pBluescript KS II(ϩ) pKS cloning vector Stratagene pPLM57 (5) pKS:Rv3485c in pBluescript This study pPLM58 (5) pKS:Rv0927c in pBluescript This study pPLM59 (5) pKS:Rv3530c in pBluescript This study pPLM60 (5) pKS:Rv3559c in pBluescript This study pPLM238 (5) pKS:mitRv1484-CTA1term in pBluescript This study YEp352
URA3-marked multicopy plasmid 27 pPLM51 (6) CTA1 behind its promoter (pYE352:CTA1) 1 6 pPLM50 (7) ETR1 behind the CTA1 promoter 50 pPLM62 (7) COQ3-mitQOR fusion behind the CTA1 promoter This study pPLM48 (8) COQ3-inhA fusion behind the CTA1 promoter (pYE352:CTA1 promoter -COQ3 MLS -inhA-CTA1 terminator )
This study a The numbers in parentheses after the strain designations indicate the parental strains, as follows: 1, strain derived from BY4741; 2, strain derived from BY4741etr1⌬; 3, strain derived from BJ1991; and 4, strain derived from BJ1991etr1⌬. Likewise, the numbers in parentheses after the plasmid designations indicate the parental plasmids, as follows: 5, plasmid derived from pBluescript KS II(ϩ); 6, plasmid derived from YEp352; 7, plasmid derived from pPLM51; 8, plasmid derived from pPLM62; 9, plasmid derived from YCplac22; and 10, plasmid derived from pYE352:mitfabI.
Rv0927c-XhoI (ϳ792 bp), BspHI-Rv3530c-HindIII (ϳ783 bp), and NcoIRv3559c-HindIII (ϳ789 bp) DNA fragments were generated by PCR essentially as described above for COQ3-inhA, using genomic DNA as the template and the corresponding oligonucleotides. The PCR products were inserted using bluntend ligation into a pBluescript KS II(ϩ) plasmid vector (pKS; Stratagene, La Jolla, CA) that was digested with EcoRV, resulting in plasmids pPLM57, pPLM58, pPLM59, and pPLM60. Following nucleotide sequencing, the inserts were transferred to the corresponding expression plasmids pPLM52, pPLM53, pPLM54, and pPLM55, as described above for COQ3-inhA. The COQ3 junction with the four inserts was verified by nucleotide sequencing. Construction of YEp352:YBR026c expressing S. cerevisiae mitochondrial ETR1 from the CTA1 promoter, which we designated YEp352:ETR1 and stored as pPLM50, has been described previously (50) . The steps used to generate the pYE352:CTA1 construct for expressing Cta1p have been described elsewhere (16) .
For low-level expression of InhA, PCR was performed with pPLM48 template DNA and oligonucleotides COQ3 MLS 5Ј NheI and CTA1 term 3Ј EcoRI, which introduced a 5Ј NheI site and a 3Ј EcoRI site, respectively, using an annealing temperature of 55°C. A single amplification product that was ϳ1.3 kb, consisting of the inhA ORF (810 bp), the CTA1 terminator (420 bp), and the COQ3 MLS (60 bp), was resolved using agarose gel electrophoresis, excised, and purified. Following ligation with an EcoRV-digested pKS plasmid to generate pPLM238, the insert was released by digesting the recombinant plasmid with NheI and EcoRI, and after electrophoresis and fragment purification, it was ligated to an XbaI-and EcoRI-digested pPLM239 plasmid, a mutant construct that did not express mitochondrially targeted E. coli FabI (see below), from which the sequence for E. coli fabI was removed, resulting in plasmid pPLM240.
Plasmid pPLM239 was constructed as follows. A COQ3 MLSmut -fabI-CTA1 terminator DNA fragment was generated by PCR amplification using primers COQ3 5Ј XbaI and CTA1 term 3Ј EcoRI and template DNA from plasmid pYE352:mitfabI (50), and the product was digested with XbaI and EcoRI prior to ligation. The ScETR1 regulatory region (974 nucleotides upstream of the ETR1 translation initiation codon) was amplified from plasmid pTSV30A:MRF1Ј (see below) with primers MRF1Ј GENE 5Ј SacI/HindIII and MRF1Јup 3Ј XbaI, and the PCR product was digested with XbaI and HindIII prior to ligation. The digested PCR products were simultaneously ligated to a HindIII-and EcoRIdigested YCplac22 plasmid (18) in a triple ligation reaction, resulting in plasmid pPLM239. After sequencing of this construct, we noticed that one of the PCR oligonucleotides was faulty since it had introduced a point mutation into COQ3 MLS , resulting in an in-frame stop codon.
Plasmid pTSV30A:MRF1Ј was constructed by PCR amplification of the ETR1 gene using the primers mentioned above and template DNA from plasmid YCplac22:MRF1Ј, restriction digestion of the PCR product with SacI and BglII, and ligation of the digested PCR product to a SacI-and BamHI-digested pTSV30A plasmid. Nonintegrating episomal plasmid pTSV30A was generated by J. Pringle and M. Longtine, and its salient features have been described previously (32) . Plasmid YCplac22:MRF1Ј (pPLM241) was constructed by PCR amplification of the ScETR1 gene, including the native promoter and terminator sequences, from yeast genomic DNA using primers MRF1Ј GENE 5Ј and MRF1Ј GENE 3ЈBglII. The product was digested with HindIII and BglII and ligated to YCplac22 (18) digested with HindIII and BamHI.
Media and growth conditions. Standard yeast (40) and E. coli (43) media were prepared as described previously. S. cerevisiae strains were propagated on solid rich glucose medium YPD, consisting of 1% (wt/vol) yeast extract, 2% (wt/vol) peptone (YP), 2% (wt/vol) D-glucose, and 2% (wt/vol) agar. Episomal plasmids were maintained in transformed strains using solid SD selective media, consisting of 0.67% (wt/vol) yeast nitrogen base without amino acids, 2% (wt/vol) D-glucose, and 2% (wt/vol) agar and supplemented with yeast synthetic drop-out medium without uracil or tryptophan (Sigma-Aldrich Inc., St. Louis, MO), as required. Cultivation of yeast cells in oleic acid medium for enzyme assays was performed as described previously (22) .
Miscellaneous. For reductase activity assays, 50-ml cultures of oleic acidgrown yeast cells were collected by centrifugation and washed twice in cold distilled water, and 300-l portions of the freshly pelleted cells were collected in 1.5-ml plastic tubes for further processing. Cells were broken with glass beads in 100 l breakage buffer that consisted of 50 mM KP i (pH 7.0), 200 mM KCl, and 0.1% (wt/vol) Triton X-100. Protein concentrations were determined by the method of Bradford (7) . Enoyl reductase activity was assayed spectrophotometrically at 23°C as described previously (15) . The assay mixture consisted of 50 mM KP i (pH 7.5), 0.1 mg/ml bovine serum albumin, 125 M NADH for InhA or 125 M NADPH for Etr1p, and 60 M 2-trans-decenoyl-CoA [trans-C 10:1(2) ] or 2-trans-hexenoyl-CoA [trans-C 6:1(2) ], which was synthesized using the mixed anhydride system (19) , as the substrate. Respiration competence was assayed by overlaying cells spotted onto solid SD-tryptophan minus medium with 0.1% (wt/vol) 2,3,5-triphenyltetrazolium chloride (TTC) in 0.067 M phosphate-buffered saline and 1.5% (wt/vol) low-melting-temperature agarose (6) . Cytochromes were monitored spectrophotometrically by measuring the absorbance between 640 and 480 nm of yeast cells applied as a thick paste onto the glass surface of an otherwise aluminum cold-temperature cuvette that was chilled in liquid nitrogen (34) . The lipoic acid content of yeast strains was monitored with a biological assay described previously (24, 26) using lipoic acid-deficient E. coli strain JRG33-lip9.
RESULTS

S. cerevisiae etr1⌬ cells expressing M. tuberculosis
InhA have 2-trans-enoyl-thioester reductase activity. To examine whether InhA or the four proteins similar to InhA were synthesized by S. cerevisiae as active 2-trans-enoyl-thioester reductases, the corresponding genes were expressed in yeast cells lacking the native mitochondrial 2-trans-enoyl-thioester reductase Etr1p. This was done by fusing the mycobacterial proteins at their N termini with the cleavable Coq3p MLS that has been demonstrated previously to be sufficient for targeting proteins to yeast mitochondria (30) (i.e., Coq3p MLS -InhA). We included the predicted MLS cleavage site (MITOPROT II) in our construct (12) . Upon entry into the mitochondria, the fused MLS is cleaved off, leaving behind the M. tuberculosis protein preceded by eight amino acids remaining from the MLS fusion (50) . The first amino acid following the native methionine of the M. tuberculosis protein was changed to accommodate the NcoI restriction site. As controls, isogenic etr1⌬ cells were transformed with plasmids for expressing either native mitochondrial Etr1p (mit-Etr1p) or peroxisomal catalase A (perCta1p). All constructs were tethered behind the yeast CTA1 promoter on URA3-marked multicopy plasmids, and yeast transformants were selected and maintained on glucose medium lacking uracil.
BY4741etr1⌬ cells expressing M. tuberculosis InhA (yPLM14) or one of the four similar proteins (yPLM29, yPLM61, yPLM30, or yPLM31) were examined to determine their enoyl-thioester reductase activity by assaying their contents for the presence of this activity using trans-C 10:1(2) as the substrate. In order to obtain high levels of protein expression from the fatty acid-inducible CTA1 promoter, cells were grown on oleic acid medium overnight prior to breakage with glass beads. The results of the enzyme assays showed that soluble protein extracts with ample mit-InhA generated from strain yPLM14 gave rise to NADH-dependent reduction of trans-C 10:1(2) at a rate of 42.1 Ϯ 5.0 nmol/mg protein min Ϫ1 (mean Ϯ standard deviation; n ϭ 3). Extracts obtained from an isogenic etr1⌬ strain (yPLM26) overexpressing native Etr1p from a similar multicopy plasmid yielded NADPH-dependent reduction of trans-C 6:1(2) at a rate of 49.6 Ϯ 3.8 nmol/mg protein min Ϫ1 (n ϭ 3). No specific enoyl-thioester reductase activity was observed in soluble protein extracts from etr1⌬ cells overexpressing per-Cta1p (yPLM25). Hence, heterologous expression of InhA in mutant etr1⌬ cells resulted in soluble protein extracts containing detectable levels of enoyl-thioester reductase activity. When the shorter trans-C 6:1 (2) was used as the substrate, the enoyl-thioester reductase activity in soluble protein extracts enriched with mit-InhA was below the detection limit of the assay used. None of the soluble protein extracts obtained from yeast transformed with plasmids for expression of mitochondrially localized versions of the four proteins resembling InhA contained reductase activity when trans-C 10:1(2) was used as the substrate. To determine whether the regeneration of 2-trans-enoyl-thioester reductase activity in the etr1⌬ mutant cells attributed to InhA could compensate for the missing native activity, BJ1991etr1⌬ cells were transformed with YCplac22-based low-copy-number centromeric plasmids marked with TRP1 (18) that carried the ETR1 or inhA genes tethered to the yeast ETR1 promoter. Transformants were selected and maintained on synthetic tryptophan-deficient glucose medium. Following overnight growth in this type of liquid medium and 10-fold serial dilution, cultures were spotted onto solid selective medium containing 2% (wt/vol) glucose or synthetic complete medium containing 3% (wt/vol) glycerol, and the plates were incubated at 30°C until single colonies were detectable.
The results demonstrated that mutant etr1⌬ cells expressing low levels of InhA (yPLM242) resembled the self-complemented strain (yPLM243) in that they grew on glycerol as a sole carbon source ( Fig. 2A) , although the cells expressing InhA gave rise to smaller colonies than the cells expressing Etr1p. As anticipated, mutant cells harboring the plasmid vector (yPLM244) were not able to grow or divide on this nonfermentable medium. The control plate consisting of tryptophan-deficient glucose medium verified both plasmid presence and the evenness of the serial dilution applied to the three strains (Fig. 2B) . None of the four InhA-like proteins were able to restore the respiratory growth of the mutant when they were produced as mitochondrial species from genes inserted into multicopy vectors (data not shown).
InhA expression repairs the mitochondrial electron transfer chain and restores lipoic acid production in the etr1⌬ mutant. A hallmark in the recovery of etr1⌬ cells from their fermentative phenotype is the assembly of cytochrome complexes. To examine this phenomenon qualitatively, transformed yeast strains were monitored spectrophotometrically for cytochrome assembly using the low-temperature cuvette method (34) . The results demonstrated that BY4741etr1⌬ cells expressing perCta1p did not assemble cytochrome b, a, and a 3 complexes (Fig. 3) , confirming previous observations (54) . The signal for these complexes was more pronounced in mutant cells expressing native mit-Etr1p or mit-InhA. To determine whether the spectrogram obtained for mutant cells producing mit-InhA correlated with a regenerated electron transfer chain, TTC was applied to a duplicate glucose plate. The results demonstrated that mutant BY4741etr1⌬ cells producing InhA were able to reduce TTC to the poorly water-soluble red chromophore, whereas the cells enriched with per-Cta1p were not able to do this (not shown). TTC was also applied to BJ1991etr1⌬ cells expressing near-physiological levels of Etr1p or InhA on the tryptophan-deficient glucose medium mentioned above (Fig.  2C) . This showed that even low levels of InhA were sufficient to cause the colonies to turn red, albeit not as efficiently as the mutants rescued with the native protein, whereas dense cells harboring the plasmid vector remained white. Hence, the combined results of these two qualitative methods led us to suggest that the ability of mutant etr1⌬ cells to grow on glycerol was due to the restoration of their mitochondrial respiratory functions.
Finally, to link InhA expression with fatty acid synthesis in yeast mitochondria, lipoic acid production in the three BY4741etr1⌬ overexpression strains was examined. As a point of reference, lipoic acid production in BY4741 or BJ1991 wildtype cells relying on their native FASII system was determined in a separate representative experiment in duplicate, and the values obtained were 254 and 218 ng lipoic acid per g, respec- tively (21) . The results of this experiment (Table 2) showed that expression of the gene for mit-InhA from a multicopy episomal plasmid in the BY4741etr1⌬ mutant resulted in a level of lipoic acid production that was equivalent to about 60% of the level observed for mutant cells expressing Etr1p. Lipoic acid measurements were also obtained using BJ1991etr1⌬ cells expressing near-physiological levels of the genes for native Etr1p or mit-InhA loaded on low-copy-number centromeric plasmids, as well as cells harboring the plasmid vector ( Table 2 ). The results demonstrated that when the inhA gene was tethered behind the ETR1 promoter on a lowcopy-number centromeric plasmid, the lipoic acid production in mutant cells was only 14% of the production in mutant cells expressing Etr1p in the same genetic context. The significance of this result is discussed below.
DISCUSSION
Here, mycobacterial InhA was shown to function in living yeast cells, as monitored by four separate biochemical and physiological examinations. First, InhA could be processed by the fungal protein synthesis machinery into an active enzyme. This, in turn, resulted in etr1⌬ mutant cells giving rise to soluble protein extracts with an enoyl-thioester reductase activity of 42.1 Ϯ 5.0 mmol/mg protein min Ϫ1 (mean Ϯ standard deviation; n ϭ 3) when trans-C 10:1(2) was used as the substrate. Although the specific enoyl-thioester reductase activity of InhA with the trans-C 6:1(2) substrate was below the detection limit of the assay used, InhA was nevertheless sufficiently active to replace native Etr1p for respiratory growth (see below). In light of the previously described data regarding the in vitro substrate specificity of InhA for medium-and long-chain (ϾC 12 ) fatty enoyl-thioesters (14, 35, 39, 41, 42) and not the short-chain species (ՅC 8 ) associated with yeast mitochondrial FASII, the present finding of functional complementation based on a much more sensitive assay relying on living cells offers a significant refinement of our knowledge of what physiological substrates InhA is able to accept in vivo.
Second, modest expression of mitochondrially targeted InhA in etr1⌬ mutant yeast cells resulted in cell growth on solid glycerol medium. Since this occurred with complemented mutant cells producing only low levels of both InhA and lipoic acid, at least compared to the self-complemented strain, this experimental design circumvented possible scenarios in which highly excessive amounts of InhA in the cells might be responsible for a suppressive effect that was not physiological. This represents an interesting and meaningful variation of previous demonstrations of an in vivo function for InhA in M. smegmatis and E. coli, in which InhA was examined with reference to increased INH resistance, since the present situation was a heterologous system outside the prokaryotes.
Third, InhA expression restored the mitochondrial electron transfer chain in the etr1⌬ mutant, as judged by the formation of cytochrome complexes and the reduction of TTC. And fourth, the expression of InhA in the etr1⌬ mutant was sufficient to support the production of lipoic acid. Although exhaustive evidence has led other workers to suggest that InhA acts physiologically only on preexisting substrates with a chain length of C 20 or more (48), here we showed that InhA could engage in de novo production of C 8 lipoic acid, in which InhA would need to act on the C 4 species 2-trans-butenoyl-thioester encountered by native Etr1p in the same process.
It is interesting that complementation of the yeast phenotype occurred in a biochemical background lacking AcpM (or any bacterial equivalent), which is important for the function of other FASII enzymes, including KasA/KasB (44), FabD (33) , and FabH (8, 11) . Moreover, InhA has been shown to interact physically with the latter four proteins in a yeast twohybrid system and coimmunoprecipitation experiments (51, 52) . Nevertheless, InhA was physiologically functional in yeast cells lacking AcpM, as well as all four interacting partners. It is not known whether the components of yeast mitochondrial FASII give rise to higher-order complexes. However, the possibility that InhA formed specific functional protein-protein a The values are means Ϯ standard deviations (n ϭ 3) and represent averages of three independent bacterial growth responses.
FIG. 3.
Spectrophotometric assay for mitochondrial cytochrome complexes. Cell pastes from the BY4741etr1⌬ strains with overexpression plasmids were collected from colonies grown on solid glucose medium that was incubated for 4 days at room temperature and applied to the glass face of otherwise aluminum low-temperature cuvettes that were immersed in liquid nitrogen before they were placed in a spectrophotometer for analysis. The pastes were scanned at wavelengths between 480 and 640 nm. The numbers on the left indicate units of absorbance (ABS), and the x axis indicates the wavelength. Peaks corresponding to known cytochromes are indicated by arrows. The strains used were yPLM14, yPLM25, and yPLM26. interactions with fungal FASII enzymes can be virtually excluded, since mycobacterial InhA is a tetramer belonging to the short-chain alcohol dehydrogenase/reductase family of proteins (14, 35, 39, 41, 42) , whereas dimeric Etr1p belongs to the medium-chain alcohol dehydrogenase/reductase family of enzymes accepting medium-length carbon chains (49) . It is also worth noting that while Etr1p depends on NADPH, InhA requires NADH for catalysis. The issue of whether InhA has functional homologues was also addressed in the present study. The mycobacterial ORFs corresponding to Rv0927c, Rv3485c, Rv3530c, and Rv3559c were processed and analyzed just like inhA was processed and analyzed. Nucleotide sequencing revealed that the four ORFs were placed correctly behind the sequence for Coq3p MLS in the appropriate expression plasmids, but whether the yeast transcription and protein synthesis machineries acted on these four ORFs to produce mitochondrial proteins was not determined. Nevertheless, we were unable to demonstrate 2-transenoyl-thioester reductase activity either in biochemical assays or complementation experiments with the yeast etr1⌬ mutant. M. tuberculosis mutants have been described for Rv0927c and Rv3485c (36) , although whether they were deficient in synthesizing mycolic acids was not reported.
In conclusion, this is the first demonstration of a physiological function for M. tuberculosis InhA within the framework of eukaryotic de novo fatty acid biosynthesis. It is at least plausible that the ability to metabolize in vivo very-short-chain fatty enoyl-thioesters might be shared by other M. tuberculosis FASII enzymes in addition to InhA and HtdZ (21) . This not only would extend the versatility of yeast FASII mutants to examining the physiological function of the remaining described mycobacterial FASII enzymes, but also might lead to the identification of unknown enzymes. This new application is especially timely since FASII is emerging as an appealing new target for novel therapeutics (9, 25) , and no new antimycolates have been developed in the past three decades, despite the pressing need for such development.
